MedicineNews.net: Drugs Medicine - Medicine News - MedicineNews.net; Xagena, Allergology , Andrology, Cardiology, Dermatology, Diabetology, Neurology, Oncology, Hematology, Rheumatology, Heaptology, Gastroenterology, Psychiatry, AbilifyAbilify Maintena, a dopamine D2 partial agonist in once-monthly ...XgevaFDA approves Xgeva for the treatment of giant cell tumor of ...DapagliflozinForxiga ( Dapagliflozin ) is the first SGLT2 ( sodium/glucose ...- MedicineNews.netSanofi and its subsidiary Genzyme have announced results from ...ErlotinibErlotinib plus Onartuzumab in advanced non-small cell lung ...CimziaThe Food and Drug Administration ( FDA ) has approved Cimzia ...RetigabineThe FDA ( Food and Drug Administration ) has warned the ...PeginterferonThe Food and Drug Administration ( FDA ) has received reports of ...AvastinAvastin plus chemotherapy for patients with metastatic ...ForxigaForxiga, a SGLT2 inhibitor, approved in Europe for ...
Medicine News & Drugs
MedicineNews.net: Drugs Medicine - Medicine News - MedicineNews.net; Xagena, Allergology , Andrology, Cardiology, Dermatology, Diabetology, Neurology, Oncology, Hematology, Rheumatology, Heaptology, Gastroenterology, Psychiatry, AbilifyAbilify Maintena, a dopamine D2 partial agonist in once-monthly ...XgevaFDA approves Xgeva for the treatment of giant cell tumor of ...DapagliflozinForxiga ( Dapagliflozin ) is the first SGLT2 ( sodium/glucose ...- MedicineNews.netSanofi and its subsidiary Genzyme have announced results from ...ErlotinibErlotinib plus Onartuzumab in advanced non-small cell lung ...CimziaThe Food and Drug Administration ( FDA ) has approved Cimzia ...RetigabineThe FDA ( Food and Drug Administration ) has warned the ...PeginterferonThe Food and Drug Administration ( FDA ) has received reports of ...AvastinAvastin plus chemotherapy for patients with metastatic ...ForxigaForxiga, a SGLT2 inhibitor, approved in Europe for ...